Sep 28

SS 15 - Immunotherapy Integration and Immuno Biomarkers Across Mucosal and Cutaneous SCC

172 - Phase 2 Trial of First-Line Camrelizumab plus Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Oral Squamous Cell Carcinoma: Outcomes and Toxicity Profile

10:55am - 11:05am ET

Screen: 7

Presenter(s)

Feng Liu, MD - Hunan Cancer Hospital, Changsha, Hunan